poisar

Stocks · News reference

Omnicell Identified as Leading Competitor in Pharmacy Automation Market Report

Fiscal.ai

A recent market report by Dataintelo identifies Omnicell as a key player in the global pharmacy automation landscape.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchZacks.Com

    Zacks.com featured highlights include Cinemark, Diamondback Energy and Omnicell

    Zacks highlights three stocks with recent broker rating upgrades as attractive investment opportunities. Cinemark Holdings expects 164.4% earnings growth in 2026, Diamondback Energy projects 68.8% earnings growth, and Omnicell anticipates 47.5% earnings growth. All three stocks hold Zacks Rank #1 ratings and have received upward broker revisions over the past four weeks.

  2. Zacks Investment ResearchNa

    Omnicell (OMCL) Q3 Earnings and Revenues Top Estimates

    Omnicell reported Q3 2026 earnings of $0.58 per share, beating consensus estimates of $0.42 by 38.10%, with revenues of $307.85 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 33.7% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 38% of Zacks industries.